XILIO THERAPEUTICS INC (XLO)
US98422T1007 - Common Stock
XILIO THERAPEUTICS INC
NASDAQ:XLO (11/22/2024, 8:14:20 PM)
After market: 0.87 -0.02 (-2.47%)0.892
-0.03 (-3.04%)
Company Profile
Xilio Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 73 full-time employees. The company went IPO on 2021-10-22. The firm is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The firm is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Company Info
XILIO THERAPEUTICS INC
828 Winter Street, Suite 300
Waltham MASSACHUSETTS
P: 16174304680
Employees: 56
Website: https://xiliotx.com/
XLO News
17 days ago - ChartmillThese stocks are moving in today's sessionWondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
17 days ago - Xilio Therapeutics, Inc.Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors17 days ago - Xilio Therapeutics, Inc.Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid TumorsCombination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses...
17 days ago - Xilio Therapeutics, Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results17 days ago - Xilio Therapeutics, Inc.Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial ResultsWill present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab,...
25 days ago - Xilio Therapeutics, Inc.Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingXLO Twits
Here you can normally see the latest stock twits on XLO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
